HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart‐Cussac, Aleix Prat, Patricia Galván et al.|The Lancet Oncology|2017Cited by 340
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterationsNoelia Martínez-Jáñez, Miguel Quintela-Fandiño|npj Precision Oncology|2025Cited by 3
Toxicity of prolonged treatment with eribulin (E) in metastatic breast cancer (MBC) patients: Results of the EXTER study.Francisco Ayala, M. Quezada Feijoo, Noelia Martínez-Jáñez et al.|Journal of Clinical Oncology|2015Cited by 0